Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Acquired Diseases
  • Published:

Anti-idiotypic DNA vaccines for lymphoma immunotherapy require the presence of both variable region genes for tumor protection

Gene Therapy volume 7, pages 605–611 (2000)Cite this article

Abstract

Vaccination with immunogenic formulations of lymphoma-derived immunoglobulin can elicit strong anti-idiotypic immune responses which have proved effective in murine B cell tumor challenge experiments and suggested possible benefits in recent human clinical trials. Naked plasmid DNA vaccines encoding the Id determinants as scFv fragments provide the most promising alternative to protein immunization. With this approach the addition of an immunogenic domain linked to the scFv has proved essential for the induction of a protective immune response. In this study we have produced a scFv gene construct linked to the CH3 exon of the human IgG1 constant region and tested its efficacy in inducing protective immunity against the mouse BCL1 lymphoma. We have also generated a second construct in which the BCL1 VL gene was deleted to investigate whether the VH region domain contains sufficient antigenic determinants for a protective immune response. Both constructs induced anti-idiotypic antibodies that specifically reacted with the BCL1 IgM protein in ELISA and with BCL1 tumor cells in flow cytometry assays. Protection against tumor challenge was fully achieved with the complete scFv construct whereas immunization with the construct lacking the VL gene resulted in only a slight prolongation of the survival. We therefore conclude that a plasmid DNA vaccine containing the VH and VL genes of the lymphoma Ig linked to the human IgG1 CH3 exon is highly effective in inducing a protective immune response in the BCL1 model. We also demonstrated that VH gene immunization can induce strong anti-idiotypic antibody responses.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Lynch RG et al. Myeloma proteins as tumor specific transplantation antigens Proc Natl Acad Sci USA 1972 69: 1540–1544

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Campbell M et al. Idiotype vaccination against murine B cell lymphoma: humoral and cellular responses elicited by tumor derived IgM and its molecular subunits J Immunol 1987 139: 2825–2833

    CAS  PubMed  Google Scholar 

  3. Kaminski MS, Kitamura K, Maloney DG, Levy R . Idiotype vaccination against murine B cell lymphoma: inhibition of tumor immunity by free idiotype protein J Immunol 1987 138: 1289–1296

    CAS  PubMed  Google Scholar 

  4. George AJT, Folkard SG, Hamblin TJ, Stevenson FK . Idiotypic vaccination as a treatment for a B cell lymphoma J Immunol 1988 141: 2168–2174

    CAS  PubMed  Google Scholar 

  5. Kwak LW et al. Induction of immune responses in patient with B cell lymphoma against the surface-immunoglobulin expressed by their tumors New Engl J Med 1992 327: 1209–1215

    Article  CAS  PubMed  Google Scholar 

  6. Hsu FJ et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma – long-term results of a clinical trial Blood 1997 89: 3129–3135

    CAS  PubMed  Google Scholar 

  7. Donnelly JJ, Ulmer JB, Shiver JW, Liu MA . DNA vaccines Annu Rev Immunol 1997 15: 617–648

    Article  CAS  PubMed  Google Scholar 

  8. Stevenson FK et al. Idiotypic DNA vaccines against B cell lymphoma Immunol Rev 1995 145: 211–228

    Article  CAS  PubMed  Google Scholar 

  9. Syrengelas AD, Chen TT, Levy R . DNA immunization induces protective immunity against B cell lymphoma Nature Med 1996 2: 1038–1041

    Article  CAS  PubMed  Google Scholar 

  10. Hakim I, Levy S, Levy R . A nine amino acid peptide from IL-1b aguments antitumor immune responses induced by protein and DNA vaccines J Immunol 1996 157: 5503–5511

    CAS  PubMed  Google Scholar 

  11. King CA et al. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma Nature Med 1998 4: 1281–1286

    Article  CAS  PubMed  Google Scholar 

  12. George AJ et al. Monoclonal antibodies raised against the idiotype of the murine B-cell lymphoma BCL1 act primarily with heavy chain determinants Hybridoma 1991 10: 219–227

    Article  CAS  PubMed  Google Scholar 

  13. Tao MH, Levy R . Idiotype/granulocyte–macrophage colony stimulating factor fusion protein as a vaccine for B-cell lymphoma Nature 1993 362: 755–758

    Article  CAS  PubMed  Google Scholar 

  14. Chen TT, Tao MH, Levy R . Idiotype-cytokine fusion proteins as cancer vaccines J Immunol 1994 153: 4775–4780

    CAS  PubMed  Google Scholar 

  15. Kwak LW et al. Vaccination with syngeneic, lymphoma derived immunoglobulin idiotype combined with granulocyte–macrophage colony-stimulating factor primes mice for a protective T-cell response Proc Natl Acad Sci USA 1996 93: 10972–10977

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Weiss R et al. A plasmid encoding murine granulocyte–macrophage colony-stimulating factor increases protection conferred by a malaria DNA vaccine J Immunol 1998 161: 2325–2332

    CAS  PubMed  Google Scholar 

  17. Lee PP et al. T-helper 2-dominant antilymphoma immune response is associated with fatal outcome Blood 1997 90: 1611–1617

    CAS  PubMed  Google Scholar 

  18. Morecki S et al. Tumor-cell vaccination induces tumor dormancy in a murine model of B cell leukemia/lymphoma (BCL1) IntJ Cancer 1996 65: 204–208

    Article  CAS  Google Scholar 

  19. George AJT, Tutt AL, Stevenson FK . Anti-idiotypic mechanism involved in suppression of a mouse B cell lymphoma, BCL1 J Immunol 1987 138: 628–634

    CAS  PubMed  Google Scholar 

  20. Li E et al. Mammalian cell expression of dimeric small immune proteins (SIP) Protein Eng 1997 10: 731–736

    Article  CAS  PubMed  Google Scholar 

  21. Watanabe A et al. Induction of antibodies to a k V region by gene immunization J Immunol 1993 151: 2871–2876

    CAS  PubMed  Google Scholar 

  22. Aba A et al. Induction of humoral and cellular anti-idiotypic immunity by intradermal injection of naked DNA encoding a human variable region gene sequence of an immunoglobulin heavy chain in a B cell malignancy Gene Therapy 1996 3: 988–993

    Google Scholar 

  23. Geissler M et al. Intracellular retention of hepatitis B virus surface proteins reduces interleukin-2 augmentation after genetic immunizations J Virol 1999 73: 4284–4292

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Lewis PJ et al. Altering the cellular location of an antigen expressed by a DNA-based vaccines modulates the immune response J Virol 1999 73: 10214–10223

    CAS  PubMed  PubMed Central  Google Scholar 

  25. Syrengelas A, Levy R . DNA vaccination against the idiotype of a murine B cell lymphoma: mechanism of tumor protection J Immunol 1999 162: 4790–4795

    CAS  PubMed  Google Scholar 

  26. Slavin S, Strobin S . Spontaneous murine B cell leukaemia Nature 1978 272: 624–626

    Article  CAS  PubMed  Google Scholar 

  27. Batista FD, Efremov DG, Burrone OR . Characterization of a second secreted igE isoforms and identification of an asymetric pathway of IgE assembly Proc Natl Acad Sci USA 1996 93: 3399–3404

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

FB was supported by a predoctoral SISSA fellowship. We are grateful to Mauro Sturnega for excellent technical assistance and to Dr Marco Bestagno for critical reading of the manuscript.

Author information

Authors and Affiliations

  1. International Centre for Genetic Engineering and Biotechnology, Area Science Park, Trieste, Italy

    F Benvenuti & O R Burrone

  2. Department of Hematology, Faculty of Medicine, Skopje, Macedonia

    D G Efremov

Authors
  1. F Benvenuti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. O R Burrone
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D G Efremov
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

DG Efremov, Department of Hematology, Faculty of Medicine, Vodnjanska 17, 91000 Skopje, Macedonia

Rights and permissions

Reprints and permissions

About this article

Cite this article

Benvenuti, F., Burrone, O. & Efremov, D. Anti-idiotypic DNA vaccines for lymphoma immunotherapy require the presence of both variable region genes for tumor protection. Gene Ther 7, 605–611 (2000). https://doi.org/10.1038/sj.gt.3301133

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gt.3301133

Keywords

This article is cited by

Search

Advanced search

Quick links